|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
A phase 2, open-label study of neoadjuvant chemotherapy plus tislelizumab followed by radiotherapy-based, bladder-preserving treatment for high risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02). |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Dodatne storitve |
|
|
© 2024 SFX by Ex Libris Inc. | Politika piškotkov
CrossRef Omogočeno
|